This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (20)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Randomized Controlled Trial  • Diagnosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Deborah M. Green, MD; Allan H. Ropper, MD

Arch Neurol. 2001;58:1098-1101.

Background  The unpredictability of the early course of Guillain-Barré syndrome (GBS) makes it difficult to determine which patients' conditions will worsen under observation. Most large randomized treatment trials for GBS have used an inability to walk as the enrollment criterion. Consequently, little is known about the treatment of those patients with milder degrees of affection.

Objectives  To determine the approximate frequency of mild GBS with the persistent ability to walk and to see if there were features that predicted that the illness would remain mild.

Setting  A registry of patients with GBS seen on the wards and in the neurology clinic from January 1,1992, to May 1, 2000, in a 400-bed community teaching hospital.

Patients  Twelve (4.7%) of 254 patients in our case series were able to walk throughout their illness. Eight had been treated with plasmapheresis or intravenous immunoglobulin; the others were observed without treatment.

Results  There was no age, sex, or seasonal preponderance in comparison with large case series that included cases of all severities. Nine of 12 patients had a preceding respiratory tract infection, 10 had paresthesias, 7 had prominent pain, and 9 had ataxia. Seven of 10 patients who were examined had normal cerebrospinal fluid protein levels. It took 8 days, on average, to reach the maximal degree of weakness. One additional treated patient, excluded from our case series, had mild weakness for the first 3 weeks and subsequently worsened with a relapsing course more typical of chronic inflammatory demyelinating polyneuropathy. Eleven patients demonstrated proximal, intermediate, or distal conduction block, and only 3 had a mild degree of denervation. There were no distinguishing clinical or electrophysiologic features between treated and untreated patients with mild GBS and, except for the mild degree of affection and the absence of substantial electromyographic changes of axonal disruption, there were no important differences between these mild cases as a group and patients who developed more severe GBS.

Conclusions  Cases of mild GBS reach a clinical nadir in a similar time to those with more severe disease. Treatment may be unnecessary in patients who are able to walk during the second week of illness, but observation until approximately the eighth day seems appropriate to be certain that the illness does not progress. In all likelihood there are mild cases of GBS that never come to the attention of a neurologist.

From the Department of Neurology, St Elizabeth's Medical Center, Boston, Mass. Dr Green is now with the Neuroscience Institute, The Queen's Medical Center, Honolulu, Hawaii.

Reprints: Deborah M. Green, MD, Neuroscience Institute, The Queen's Medical Center, 1301 Punchbowl St, Honolulu, HI 96813 (e-mail: dgreen{at}queens.org).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2001;58(7):1172-1174.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Economic cost of Guillain-Barre syndrome in the United States
Frenzen
Neurology 2008;71:21-27.
ABSTRACT | FULL TEXT  

Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barre Syndrome: A Randomized Trial
Korinthenberg et al.
Pediatrics 2005;116:8-14.
ABSTRACT | FULL TEXT  

Use of Cellular and Plasma Apheresis in the Critically Ill Patient: Part II: Clinical Indications and Applications
Linenberger and Price
J Intensive Care Med 2005;20:88-103.
ABSTRACT  

Practice parameter: Immunotherapy for Guillain-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Latov and Hughes
Neurology 2004;62:1653-1654.
FULL TEXT  

Differences in patterns of progression in demyelinating and axonal Guillain-Barre syndromes
Hiraga et al.
Neurology 2003;61:471-474.
ABSTRACT | FULL TEXT  

Infections and course of disease in mild forms of Guillain-Barre syndrome
Van Koningsveld et al.
Neurology 2002;58:610-614.
ABSTRACT | FULL TEXT  

Mild Guillain-Barre Syndrome: How Should It Be Managed?
JWatch Neurology 2001;2001:4-4.
FULL TEXT